Sernova Appoints Clinical Advisory Board To Guide Type 1 Diabetes Cell Pouch Program

Sernova Biotherapeutics, a leader in regenerative medicine, has announced the formation of a Clinical Advisory Board to support the advancement of its Cell Pouch Bio-hybrid Organ, a novel therapeutic platform aimed at providing a functional cure for type 1 diabetes (T1D). 

Five leading experts will be part of the Clinical Advisory Board, chaired by Dr. Robert Gabbay, a Harvard Medical School professor who used to oversee the research and medical research plans for the American Diabetes Association. Experts from around the world in diabetes research, pancreatic cell transplant and tissue regeneration work together to direct the clinical and translational strategies for the Cell Pouch platform.

In addition to Dr. Gabbay, members of the board are Dr. Mark Atkinson (University of Florida), Dr. Melena Bellin (University of Minnesota), Dr. Andrew Posselt (UCSF Medical Center) and Dr. Holger Russ (University of Florida). The team’s knowledge in immunology, beta-cell biology, transplantation and pediatric endocrinology will be important as Sernova prepares for further clinical trials and potential commercialization of its T1D therapy.